SR141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats

Behavioural Pharmacology

Volumn 10, Issue 3, 1999, Pages 327-331

  Costa, B ^a   Vailati, S ^a   Colleoni, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anandamide; Behaviour; Cannabinoid; Cannabinoid receptor antagonist; Rat; SR 141716A

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT; CANNABINOID RECEPTOR; DRUG RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DEFECATION; GROOMING; HOT PLATE TEST; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; REARING; TAIL FLICK TEST; ANIMAL; AROUSAL; BRAIN; DRUG ANTAGONISM; DRUG EFFECT; MOTIVATION; MOTOR ACTIVITY; PAIN THRESHOLD; SPRAGUE DAWLEY RAT;

ANIMALS; AROUSAL; BRAIN; MALE; MOTIVATION; MOTOR ACTIVITY; PAIN THRESHOLD; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0032586373     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199905000-00009     Document Type: Article

References (27)

1. Adams IB, Compton DR, Martin BR (1998). Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217.
2. Brodkin J, Moerschbaecher JM (1997). SR 141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats. J Pharmacol Exp Ther 282:1526-1532.
3. Calignano A, La Rana G, Makriyannis A, Lin SY, Beltramo M, Piomelli D (1997). Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol 340:R7-R8.
4. Compton DR, Rice KC, de Costa BR, Razdan RK, Melvin LS, Johnson MR et al. (1993). Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226.
5. D'Amour FE, Smith DL (1941). A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
6. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
7. Eddy NB, Fuhrmeister Touchberry C, Lieberman JE (1953). Synthetics analgesics. I. Methadon isomers and derivatives. J Pharmacol 98:121-137.
8. Fernàndez-Ruiz JJ, Munoz RM, Romero J, Villanua MA, Makryannis A, Ramos JA (1997). Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochem Pharmacol 53:1919-1927.
9. Fride E, Mechoulam R (1993). Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231:313-314.
10. Gad S, Weil CS (1988). Fisher's exact test. In: Statistics and experimental design for toxicologists. Caldwell, NJ: Telford Press, pp. 54-55.
11. Kulkarni SK, Ninan I, George B (1996). Anandamide: an endogenous cannabinoid. Drugs of Today 32:275-285.
12. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor: functional expression of the cloned cDNA. Nature 346:561-563.
13. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
14. Pertwee RG (1972). The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmacol 46:753-763.
15. Pertwee RG (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
16. Richardson JD, Kilo S, Hargreaves KM (1998). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119.
17. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C et al. (1994) SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
18. Rodriguez de Fonseca F, Carrera MRA, Navarro M, Koob GF, Weiss F (1997). Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276:2050-2054.
19. Romero J, Garcia L, Cebeira M, Zadrozny D, Fernandez-Ruiz JJ, Ramos JA (1995). The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behaviour: role of nigrostriatal dopaminergic neurons. Life Sci 56:2033-2040.
20. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994a). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227.
21. 9-tetrahydrocannabinol and k opioids in mice. J Pharmacol Exp Ther 268:1381-1387.
22. Souilhac J, Poncelet M, Rinaldi-Carmona M, Le Fur G, Soubrié P (1995). Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol Biochem Behav 51:3-7.
23. Stein EA, Fuller SA, Edgemond WS, Campbell WB (1996). Physiological and behavioral effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol 119:107-114.
24. Varga K, Lake K, Martin BR, Kunos G (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278:279-283.
25. Welch SP, Huffman JW, Lowe J (1998). Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR 141716A. J Pharmacol Exp Ther 286:1301-1308.
26. Wenger T, Jamali KA, Juaneda C, Leonardelli J, Tramu G (1997). Arachidonylethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem Biophys Res Commun 237:724-728.
27. 9-tetrahydro-cannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.